尼古丁通过高调节Grem1表达来加剧糖尿病病
Jianning Chen1, Haiting Xiao2, Rui Xue1
1Affiliated Mental Health Center and Hangzhou Seventh People's Hospital, Zhejiang University School of Medicine, Hangzhou, 310000, Zhejiang, China.
Molecular medicine (Cambridge, Mass.)
|July 6, 2023
概括
尼古丁通过增加Grem1的表达,使糖尿病病 (DN) 恶化,导致损伤. 针对Grem1可能有助于治疗DN的吸烟者.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 毒理学 毒理学 毒理学
背景情况:
- 糖尿病病 (DN) 是一种严重的糖尿病并发症.
- 吸烟是已知的危险因素,可加剧DN患者的损伤.
- 连接吸烟和DN的分子机制尚未完全理解.
研究的目的:
- 研究尼古丁加剧糖尿病病 (DN) 的分子机制.
- 在糖尿病小鼠模型中探索Grem1在尼古丁诱导的损伤中的作用.
主要方法:
- 一个糖尿病小鼠模型是使用链毒素 (STZ) 建立的.
- 用尼古丁或PBS治疗小鼠,并评估损伤标志物.
- 分子分析包括RNA-seq,实时PCR,西斑和免疫组织化学.
- 在体外研究中使用了抑制格雷姆1表达的人类细胞.
主要成果:
- 单独的尼古丁并没有导致损伤,但显著恶化了高血糖诱导的标记物,如白蛋白尿和BUN.
- 结合尼古丁和高血糖症显著增加了Grem1表达,并加剧了DN.
- 抑制Grem1表达在体外减弱的尼古丁诱导的 podocyte 损伤.
结论:
- 在尼古丁加剧的糖尿病病中,Grem1起着至关重要的作用.
- Grem1代表了患有DN的慢性吸烟者潜在的治疗标.
相关概念视频
Drugs Acting on Autonomic Ganglia: Stimulants
1.4K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
1.4K
Pathophysiology of Diabetes
1.0K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.0K
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Diabetes Mellitus: Overview and Type I Subtype
2.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K
Oral Hypoglycemic Agents: Glinides
189
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
189


